Rise Nano Optics Confirms FDA Status and First US Lab Partner, Yet Commercialization Scale Remains Unproven
Market One: Rise Nano Optics Secures First U.S. Lab Partnership as SPECTRAGUARD(TM) Commercialization Advances
Healthcare
Page 29- Apr 23, 2026 · 08:01 · BPC · Neutral01
Management pivots to commercial spend amid regulatory clarity, but revenue visibility remains absent
The Precision Peptide Company Announces Strategic Product Marketing Agreement
- Apr 23, 2026 · 08:00 · LOBE · Routine +02
Balance Sheet Restructuring and Regulatory Tailwinds Support Pipeline Progress
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
- Apr 23, 2026 · 08:00 · VST · Routine +03
Pawsible Ventures Cohort Launch Validates Victory Square Diversification Strategy as Hydreight Scales
Pawsible Ventures Unveils First Cohort Targeting the $300B Pet Health Opportunity
- Apr 23, 2026 · 07:30 · MRVL · Routine +04
Marvel Biosciences Secures Funding and Patent Protection for Phase 1 Neurodevelopmental Candidate MB-204
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
- Apr 23, 2026 · 07:00 · CNVI · Routine +05
Conavi Medical Awarded 2026 TAG Innovation
Conavi Medical Awarded 2026 TAG Innovation Award
- Apr 23, 2026 · 07:00 · BLCO · Routine +06
Bausch + Lomb Executes H1 Roadmap with AREDS3 Launch Amidst Debt Refinancing and Earnings Growth
Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration
- Apr 22, 2026 · 19:13 · CTX · Routine +07
Crescita Therapeutics Moves Closer to ClinActiv Takeover at $0.80 Premium
Crescita Announces Filing and Mailing of Special Meeting Materials and Receipt of Interim Order in respect of Arrangement with ClinActiv Holdings
- Apr 22, 2026 · 16:17 · ALZI · Routine +08
Alzai Health Files Final Prospectus for $4M Best-Efforts IPO
Alzai Health Corp. Files Final Prospectus in Connection With Initial Public Offering
- Apr 22, 2026 · 09:16 · QNTM · Routine +09
Unbuzzd CEO Appointment Signals Commercial Push Amidst MS Pipeline Progress
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
- Apr 22, 2026 · 08:23 · VVTM · Routine +10
VVT Med Secures First Tranche Financing Amid Regulatory Filing Delays
VVT Med Closes $1,065,664 First Tranche of Private Placement of Units
- Apr 22, 2026 · 07:15 · BLCO · Routine +11
Sustainability Report Confirms Long-Term ESG Goals
Bausch + Lomb Releases 2025 Sustainability Impact Report
- Apr 22, 2026 · 07:00 · GREY · Routine −12
Grey Matters Health Raises Capital at Discount to Fund US Clinic Expansion Amidst Dilution Concerns
Grey Matters Announces Private Placement
- Apr 22, 2026 · 07:00 · AIAI · Routine +13
NetraMark Capitalizes on Psychedelic Regulatory Tailwinds Amidst Price Consolidation
NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs
- Apr 22, 2026 · 07:00 · EPRX · Routine +14
Eupraxia Confirms Durable Efficacy and Safety Profile Ahead of Phase 2b Top-Line Readout
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting